Oncolytics Biotech (TSE:ONC) Sets New 52-Week Low – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$1.03 and last traded at C$1.05, with a volume of 63494 shares changing hands. The stock had previously closed at C$1.05.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a market capitalization of C$83.01 million, a PE ratio of -2.84 and a beta of 1.35. The company has a 50 day moving average price of C$1.26 and a 200 day moving average price of C$1.38.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same quarter in the previous year, the business earned ($0.14) EPS. Equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.